Skip to Content

Evolution of MS Treatments

Henrik Ahvenjarvi, MD, PhD student from the University of Oulu, conducted a retrospective study, along with his team, on the evolution of initial disease-modifying treatments for relapse remitting multiple sclerosis in Finland from 2013 to 2022. Among others, the study showed an increase in high efficacy treatments from 7% to 44%, with a decrease in medium efficacy treatments. Watch the MEDtalk and find out more.

Henrik Ahvenjarvi

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top